Commerzbank Analysts Give Bayer (BAYN) a €111.00 Price Target

Commerzbank set a €111.00 ($129.07) target price on Bayer (FRA:BAYN) in a research note issued to investors on Friday morning. The brokerage currently has a buy rating on the healthcare company’s stock.

Several other equities research analysts have also recently commented on the stock. Deutsche Bank set a €127.00 ($147.67) price target on shares of Bayer and gave the stock a buy rating in a research report on Friday. Baader Bank set a €140.00 ($162.79) price target on shares of Bayer and gave the stock a buy rating in a research report on Wednesday, July 11th. Independent Research set a €85.00 ($98.84) price target on shares of Bayer and gave the stock a neutral rating in a research report on Wednesday, September 5th. JPMorgan Chase & Co. reissued a buy rating on shares of Bayer in a research report on Friday. Finally, DZ Bank reissued a buy rating on shares of Bayer in a research report on Monday, July 16th. Seven research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of €97.45 ($113.32).

Shares of FRA BAYN opened at €70.09 ($81.50) on Friday. Bayer has a 1-year low of €91.58 ($106.49) and a 1-year high of €123.82 ($143.98).

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Further Reading: How analysts view the yield curve

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply